04:40 PM EDT, 03/16/2026 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Monday that four sub-studies from its EMANATE trial did not meet primary endpoints, sending shares down nearly 6% in recent after-hours trading.
The trial, which tested the drug setmelanotide in patients with rare, genetically driven obesity of the MC4R pathway, showed no new safety signals.